Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma

Abstract: Elotuzumab is a monoclonal antibody targeting signaling lymphocyte activation molecule F7 on plasma and natural killer cells, which enhances the activity of lenalidomide, pomalidomide, and bortezomib in multiple myeloma (MM). The OPTIMISMM study showed improved outcomes with the combinatio...

Full description

Bibliographic Details
Main Authors: Andrew J. Yee, Jacob P. Laubach, Erica L. Campagnaro, Brea C. Lipe, Omar Nadeem, Robb S. Friedman, Craig E. Cole, Elizabeth K. O’Donnell, Giada Bianchi, Andrew R. Branagan, Robert L. Schlossman, Samantha J. Shapiro, Cynthia C. Harrington, Jill N. Burke, Marilyn T. Gammon, Kathleen J. Lively, Cassandra A. Reimonn, Danielle X. Andrade, Robert Redd, Jens G. Lohr, Kenneth C. Anderson, Paul G. Richardson, Noopur S. Raje
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952924006943

Internet

http://www.sciencedirect.com/science/article/pii/S2473952924006943

Similar Items